Background
Human studies of miR-650
Expression of miR-650 in cancers
Hepatocellular carcinoma (HCC)
miR-650 and lung cancer (LC)
miR-650 and colorectal cancer (CRC)
miR-650 and gastric cancer (GC)
miR-650 and glioma
miR-650 and melanoma
miR-650 and leukaemia
Other tumours
Cancer type | Expression | Samples | Clinical significance | References |
---|---|---|---|---|
HCC | Upregulated | Tissues from 130 HCC patients | Microscopic vascular invasion, tumour volume, TNM stage | [30] |
HCC | Upregulated | / | / | [31] |
HCC | Upregulated | 248 HCC tissues and 120 paracarcinomatous HCC tissues | Age, differentiation capability, tumour stage | [34] |
FLD/HCC | Upregulated | / | Tumour metastasis | [32] |
NSCLC | Upregulated | 53 NSCLC tissues and adjacent normal lung tissues | / | [64] |
NSCLC | Upregulated | 49 NSCLC tissues and adjacent normal tissues | Overall survival rate | [13] |
NSCLC | Upregulated | / | / | [37] |
LAD | Upregulated | 96 LAD tissues and adjacent normal tissues, 44 LAD tissues (received docetaxel-based chemotherapy) | Lymph node metastasis, tumour stage, overall survival rate, docetaxel resistance | [16] |
CRC | Downregulated | Tissues from 96 CRC patients | Overall survival rate | [39] |
CRC | Upregulated | 45 rectal cancer tissues, 22 colon cancer tissues, adjacent noncancerous tissues | Oxaliplatin resistance, tumour growth | [40] |
CRC(bioinf) | Downregulated | Tissues from 217 CRC patients | / | [41] |
CRC | Upregulated | Tissues from 70 CRC patients | Lymph node metastasis | [42] |
CRC | Upregulated | / | / | [14] |
GC(bioinf) | Upregulated | Tissues from 90 GC patients, tissues from 90 pre-GC patients, tissues from 45 healthy controls | / | [45] |
GC | Upregulated | Tissues from 119 GC patients | Overall survival rate | [46] |
GC | Upregulated | 93 GC tissues and adjacent normal tissues, 44 LAD tissues (received docetaxel-based chemotherapy) | Tumor growth | [47] |
GC | Upregulated | Primary GC tissues | Lymphatic and distant metastasis | [15] |
Glioma | Upregulated | 168 glioma tissues and 21 normal contral tissues | WHO grade, KPS score, overall survival rate | [49] |
Glioma | Upregulated | Tissues from 39 glioma patients | Tumour formation and growth | [50] |
Glioma | Downregulated | Tissues from 24 glioma patients | / | [51] |
Melonoma | Downregulated | Tissues from 309 melonoma patients | TNM stage, overall survial, progression-free survival | [19] |
Melonoma | Downregulated | / | / | [56] |
CLL | Downregulated | Peripheral blood from 80 CLL patients and healthy controls | / | [24] |
CLL | Upregulated | Peripheral blood from 102 CLL patients and 40 healthy controls | Binet stage, lactate dehydrogenase (LDH) level, time for first treatment | [59] |
ALL | Downregulated | / | Prognosis | [58] |
AML | Downregulated | Bone marrow and peripheral blood from 40 AML patients and 35 healthy controls | / | [57] |
BC | Upregulated | Tissues from BC patients | / | [60] |
EC | Upregulated | 60 EC tissues and adjacent normal tissues | Tumour size, TNM stage, lymph and distant metastasis | [11] |
ATC | Upregulated | 12 PTC tissues, 5 ATC tissues, 6 normal tissues | / | [61] |
Osteosarcoma | Upregulated | / | / | [18] |
OC | Upregulated | / | Tumour weight and volume | [62] |
PC | Upregulated | 216 PC tissues, 324 benign prostate tissues, 77 normal tissues | Tumour volume, tumour metastasis, mortality of severe | [63] |
Cancer type | Cell lines | Upstream | Target | Roles | Function | References |
---|---|---|---|---|---|---|
HCC | HCC cell and LO2 | / | LAST2 | Tumour promoter | Promotes cell proliferation, migration and invasion; increases cell EMT | [30] |
HCC | LO2, SK-HEP-1, HUH-7, LM6 and Li-7 | AXIN1 | / | Tumour promoter | Promotes cell proliferation, migration and invasion; increases cell EMT | [31] |
HCC | THLE-2 (CRL-2706, ATCC) | / | ING4 | Tumour promoter | Promotes cell proliferation | [34] |
FLD/HCC | SMMC-7721 and BEL-7404 | Benzo[a]pyrene | SOCS3/JAK/STAT3 | Tumour promoter | Promotes cell motility | [32] |
NSCLC | H23, H522, A549, H1299, SPC-A1, 16HBE, HEK293T | / | LATS2 | Tumour promoter | Promotes cell proliferation, migration and invasion | [64] |
NSCLC | A549, NCI-H460, MRC-5 | / | ING4 | Tumour promoter | Promotes cell proliferation and invasion | [13] |
NSCLC | cell line H1299, 293T | LncRNA MEG3 | SLC34A2 | Tumour promoter | Promotes cell migration and invasion; strengthens stem cell-like characteristics | [37] |
LAD | SPC-A1, NCI-H1299 | / | ING4/Bcl-2/Bax | Tumour promoter | Promotes cell growth; enhances the resistance of LAD cells to docetaxel; reduces the sensitivity of LAD cells to docetaxel | [16] |
CRC | DLD-1, HCT-8, HEK293T | / | AKT2/GSK3β/E-cadherin pathway | Tumour suppressor | Suppresses cell proliferation, migration and invasion | [39] |
CRC | Caco2 and HT29 | LncRNA MIR155HG | ANXA2 | Tumour promoter | Promotes M2 macrophage polarization and cell proliferation, migration, invasion and oxaliplatin resistance | [40] |
CRC(bioinf) | / | NF-κB | NF-κB signalling pathway | Tumour suppressor | / | [41] |
CRC | SW480, HT29, SW620, LOVO | / | NDRG2 | Tumour promoter | Promotes cell growth; suppresses cell differentiation and apoptosis | [42] |
CRC | SW480, SW620, RKO, 320DM, 320HSR, NCI-H716, H508, CCD841CoN | / | RhoA/Rac1 GTPase + ING4/ERK/p38 MAPK | Tumour promoter | Promotes cell proliferation and migration; increases cell EMT | [14] |
GC(bioinf) | / | / | / | Tumour promoter | / | [45] |
GC | HGC-27, MKN-45 cells, HEK293T | PBX1 | LATS2 | Tumour promoter | Promotes cell proliferation, invasion and migration; suppresses cell apoptosis | [46] |
GC | AGS, HGC-27, MGC-803, SGC-7901, GES-1 | LncRNA DICER-AS1 | CSR1 | Tumour promoter | Promotes cell proliferation, migration; suppresses cell apoptosis | [47] |
GC | SNU-16, NCI-N87 | / | ING4 | Tumour promoter | Promotes cell proliferation and tumorigenesis | [15] |
Glioma | / | / | / | Tumour promoter | / | [49] |
Glioma | U251, LN229, U373, A172, U87, NHA | NF-κB | RERG-PHLPP2/AKT + ERK + NF-κB | Tumour promoter | Promotes cell proliferation, autophagy, migration and invasion; increases EMT | [50] |
Glioma | LN229, U87, U251, LN308, SNB19, H4 | / | FAM83F | Tumour suppessor | Promotes cell proliferation | [51] |
Melonoma | A375, MV3 | LncRNA POU3F3 | / | Tumour suppessor | Reduces MGMT-induced DTIC resistance; suppress cell proliferation | [19] |
Melonoma | M21, SK-MEL-1, A2058, A375, HEMa-LP | LncRNA ZFPM2-AS1 | Notch1 | Tumour suppessor | Promotes cell proliferation and migration; suppresses cell apoptosis | [56] |
CLL | NALM-6 | host gene for IgLλ | CDK1 ING4 EBF3 | Tumour suppessor | Suppresses proliferative capacity of B cells | [24] |
CLL | CLL cells | / | NDRG2 | Tumour promoter | Suppresses cell apoptosis | [59] |
ALL | REH, NALM-6, UT-7 | / | GATA2/EPOR | Tumour suppressor | / | [58] |
AML | K562 cells | / | Gfi1 | Tumour suppressor | Suppresses cell proliferation | [57] |
BC | UIVC-IDC-6, -9, -10 | 22q11.2 gene | ING4 NDRG2 | Tumour promoter | Increases cell EMT | [60] |
EC | HEC-1B, HEC-1 A, Ishikawa, RL-952, hEEC | LncRNA MCTP1-AS1 | SMAD7/TGF-β/SMAD pathway | Tumour promoter | Promotes cell proliferation, migration and invasion; increases EMT | [11] |
ATC | TPC-1, CAL62, SW1736, 8505 C | / | PPP2CA | Tumour promoter | Promotes cell migration and invasion | [61] |
Osteosarcoma | MG-63 | / | NFκB + ING4/IL-6 | Tumour promoter | / | [18] |
OC | hTERT-OME, SCC-15, SCC-4, SCC-9, SCC-25, CAL-27, FaDu, 019 | / | Gfi1 | Tumour promoter | Promotes cell proliferation, migration and
invasion | [62] |
PC | PC3, DU145 | / | CSR1 | Tumour promoter | Promotes cell growth and DNA replication | [63] |